Compare AbbVie Inc (ABBV) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Global X Autonomous & Electric Vehicles — how do they compare? AbbVie Inc trades at $253.75 (market cap $449.91B), while Global X Autonomous & Electric Vehicles trades at $35.71. The key difference: AbbVie Inc pays a 2.72% dividend while Global X Autonomous & Electric Vehicles pays none, and AbbVie Inc is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| ABBV | DRIV | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $42.53 |
52-Week Low | $184.85 | $23.67 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
DRIV trades at $37.63, up 2.42% today, but technical signals are bearish with moving averages indicating selling pressure. The stock faces industry headwinds from shifting consumer demand and geopolitical tensions affecting fuel prices. Recent news highlights competitive threats from Chinese EV makers and regulatory uncertainties in the U.S. market, while a dividend of $0.07 is scheduled for July 2026.
Outlook remains cautious due to bearish technicals and sector volatility. Investment opportunities lie in exposure to autonomous driving and EV growth, but risks include intense competition, regulatory changes, and macroeconomic pressures. Wall Street sentiment is mixed, reflecting the ETF's diversified tech and auto holdings amid evolving market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
